Biliary Tract Cancer

Common Name(s)

Biliary Tract Cancer

Bile Tract Cancer is a rare digestive cancer characterized by abnormal cell growth in the bile ducts and gallbladder. Individuals with this disorder may grow harmful tumors that can spread to the rest of the body if not diagnosed early. The bile duct system is responsible for storing and transporting bile from the liver, where it is made, to the intestines, where it helps to digest food. Incomplete development of the ducts inhibits the flow of bile. Individuals with this defect have digestion problems as well as a yellow discoloration of the eye and skin (jaundice). Doctors are usually able to diagnose this defect early in the abnormal growth process, as the resulting symptoms are quickly apparent. Treatment is developed on a case-by-case basis and depends on the specific needs of the patient. For prevention measures, digestion specialists may suggest individuals eat a lower-fat diet, or undergo surgery to relieve the blockage or create a tube to allow bile to reach the digestive system. If an individual's cancer has progressed, doctors may suggest chemotherapy to combat cancer symptoms.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Biliary Tract Cancer" returned 83 free, full-text research articles on human participants. First 3 results:

Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer.
 

Author(s): Jan Harder, Michael J Müller, Matthias Fuchs, Vera Gumpp, Annette Schmitt-Graeff, Richard Fischer, Melanie Frank, Oliver Opitz, Jens Hasskarl

Journal: World J. Gastroenterol.. 2013 Dec;19(48):9334-42.

 

To investigate the expression and clinical relevance of inhibitor of differentiation (ID) proteins in biliary tract cancer.

Last Updated: 10 Jan 2014

Go To URL
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
 

Author(s): Kyoichi Kaira, Yutaka Sunose, Yasuhiro Ohshima, Noriko S Ishioka, Kazuhisa Arakawa, Tetsushi Ogawa, Noriaki Sunaga, Kimihiro Shimizu, Hideyuki Tominaga, Noboru Oriuchi, Hideaki Itoh, Shushi Nagamori, Yoshikatsu Kanai, Aiko Yamaguchi, Atsuki Segawa, Munenori Ide, Masatomo Mori, Tetsunari Oyama, Izumi Takeyoshi

Journal:

 

The expression of L-type amino acid transporter 1 (LAT1) has been described to play essential roles in tumor cell growth and survival. However, it remains unclear about the clinicopathological significance of LAT1 expression in biliary tract cancer. This study was conducted to determine ...

Last Updated: 11 Dec 2013

Go To URL
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
 

Author(s): Akihiro Murata, Ryosuke Amano, Nobuya Yamada, Kenjiro Kimura, Masakazu Yashiro, Bunzo Nakata, Kosei Hirakawa

Journal:

 

Gemcitabine is a pyrimidine nucleoside analog that is a commonly used chemotherapeutic agent for unresectable or recurrent biliary tract cancer (BTC). Several molecules involved in gemcitabine metabolism, including human equilibrative nucleoside transporter (hENT1), deoxycytidine ...

Last Updated: 3 Jun 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Biliary Tract Cancer" returned 5 free, full-text review articles on human participants. First 3 results:

Current status of chemotherapy for the treatment of advanced biliary tract cancer.
 

Author(s): Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Kazuhiko Koike

Journal: Korean J. Intern. Med.. 2013 Sep;28(5):515-24.

 

Chemotherapy is indispensable for the treatment of advanced biliary tract cancer. Recently, reports regarding first-line chemotherapy have increased, and first-line chemotherapy treatment has become gradually more sophisticated. Gemcitabine and cisplatin combination therapy (or gemcitabine ...

Last Updated: 6 Sep 2013

Go To URL
Current status of immunotherapy for the treatment of biliary tract cancer.
 

Author(s): Ryuji Takahashi, Munehiro Yoshitomi, Shigeru Yutani, Takahisa Shirahama, Masanori Noguchi, Akira Yamada, Kyogo Itoh, Tetsuro Sasada

Journal: Hum Vaccin Immunother. 2013 May;9(5):1069-72.

 

Biliary tract cancer (BTC) is one of the most aggressive malignancies. Although various promising regimens of chemotherapeutic and/or molecular targeted agents have been developed, further treatment modalities, including immunotherapies, still remain to be established for refractory ...

Last Updated: 7 Oct 2013

Go To URL
Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.
 

Author(s): J R A Skipworth, S W M Olde Damink, C Imber, J Bridgewater, S P Pereira, M Malagó

Journal: Aliment. Pharmacol. Ther.. 2011 Nov;34(9):1063-78.

 

The majority of patients with cholangiocarcinoma present with advanced, irresectable tumours associated with poor prognosis. The incidence and mortality rates associated with cholangiocarcinoma continue to rise, mandating the development of novel strategies for early detection, improved ...

Last Updated: 10 Oct 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Second Line Therapy in Advanced Biliary Tract Cancer
 

Status: Recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 9 Feb 2012

Go to URL
Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer
 

Status: Recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 9 Dec 2011

Go to URL

Last Updated: 5 Apr 2013

Go to URL